HUMA
Price
$5.45
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
48 days until earnings call
RXRX
Price
$6.94
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
47 days until earnings call
Ad is loading...

HUMA vs RXRX

Header iconHUMA vs RXRX Comparison
Open Charts HUMA vs RXRXBanner chart's image
Humacyte
Price$5.45
Change-$0.00 (-0.00%)
Volume$1.56M
CapitalizationN/A
Recursion Pharmaceuticals
Price$6.94
Change-$0.00 (-0.00%)
Volume$4.63M
CapitalizationN/A
View a ticker or compare two or three
HUMA vs RXRX Comparison Chart
Loading...
HUMA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
HUMA vs. RXRX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HUMA is a Hold and RXRX is a Hold.

COMPARISON
Comparison
Sep 21, 2024
Stock price -- (HUMA: $5.34 vs. RXRX: $6.91)
Brand notoriety: HUMA and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HUMA: 55% vs. RXRX: 126%
Market capitalization -- HUMA: $620.63M vs. RXRX: $1.92B
HUMA [@Biotechnology] is valued at $620.63M. RXRX’s [@Biotechnology] market capitalization is $1.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $595.57B to $0. The average market capitalization across the [@Biotechnology] industry is $2.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HUMA’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • HUMA’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both HUMA and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HUMA’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • HUMA’s TA Score: 5 bullish, 5 bearish.
  • RXRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than HUMA.

Price Growth

HUMA (@Biotechnology) experienced а -6.15% price change this week, while RXRX (@Biotechnology) price change was +7.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.40%. For the same industry, the average monthly price growth was +1.46%, and the average quarterly price growth was -0.90%.

Reported Earning Dates

HUMA is expected to report earnings on Nov 07, 2024.

RXRX is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+0.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.92B) has a higher market cap than HUMA($621M). HUMA YTD gains are higher at: 88.028 vs. RXRX (-29.919). HUMA has higher annual earnings (EBITDA): -124.91M vs. RXRX (-348.35M). RXRX has more cash in the bank: 474M vs. HUMA (93.6M). HUMA has less debt than RXRX: HUMA (17.9M) vs RXRX (89.9M). RXRX has higher revenues than HUMA: RXRX (48.6M) vs HUMA (0).
HUMARXRXHUMA / RXRX
Capitalization621M1.92B32%
EBITDA-124.91M-348.35M36%
Gain YTD88.028-29.919-294%
P/E RatioN/AN/A-
Revenue048.6M-
Total Cash93.6M474M20%
Total Debt17.9M89.9M20%
TECHNICAL ANALYSIS
Technical Analysis
HUMARXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 8 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 18 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
HUMA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSCYX28.840.05
+0.17%
Hartford Small Company Y
PASSX62.130.10
+0.16%
T. Rowe Price Small-Cap Stock Adv
HFSSX13.510.02
+0.15%
Hartford Schroders Intl Cntrrn Val SDR
DWGHX10.85-0.01
-0.09%
American Funds Dvlpg Wld Gr&Inc F2
TNBRX19.20-0.08
-0.42%
1290 SmartBeta Equity R

HUMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, HUMA has been loosely correlated with RXRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HUMA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUMA
1D Price
Change %
HUMA100%
+2.10%
RXRX - HUMA
49%
Loosely correlated
+2.22%
ABCL - HUMA
42%
Loosely correlated
+0.73%
VIR - HUMA
37%
Loosely correlated
-1.64%
CRSP - HUMA
37%
Loosely correlated
-0.56%
BEAM - HUMA
37%
Loosely correlated
-0.27%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+2.22%
BEAM - RXRX
61%
Loosely correlated
-0.27%
NTLA - RXRX
58%
Loosely correlated
-0.13%
CRSP - RXRX
56%
Loosely correlated
-0.56%
PRME - RXRX
55%
Loosely correlated
-0.50%
RCKT - RXRX
53%
Loosely correlated
-4.40%
More